Oncternal Therapeutics Reverse Merges with GTx

 Oncternal Therapeutics Reverse Merges with GTx

Oncternal Therapeutics Reverse Merges with GTx

Shots:

  • With the closure of the transaction, Oncternal Therapeutics will be listed on Nasdaq under the ticker ONCT
  • Oncternal’s stockholders will hold 75% of the shares of combined company and GTx will retain 25% of shares. GTx stockholders will receive 50% non-transferable contingent value rights (CVR) from the grant, sale or transfer of rights to SARD
  • The newly merged company have strong Octernal’s oncology portfolio with GTx’s Selective Androgen Receptor Degrader (SARD) technology for castration-resistant prostate cancer

Click here to read full press release/ article | Ref: Oncternal | Image: GMP news

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post